echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > FDA plans to approve drug reports in May

    FDA plans to approve drug reports in May

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileKe Ke

    May is an extremely busy month on the FDA's new drug review calendar.


    Heron Therapeutics: New drug HTX-011 for postoperative pain

    The target action date for the New Drug Application Application (NDA) of HTX-011 for the treatment of postoperative pain is May 12, 2021.


    HTX-011 is a non-opioid analgesic, a dual-acting, fixed-dose combination of local anesthetic bupivacaine and low-dose non-steroidal anti-inflammatory meloxicam.


    In September 2020, the European Commission (EC) granted HTX-011 a marketing authorization for drugs marketed under the Zynelef brand for somatic postoperative pain in adult small and medium surgical wounds.


    Apellis Pharma: Pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH)

    The Apellis drug has a target action date of May 14 for the treatment of PNH, a rare blood disease that causes red blood cells to divide (hemolysis).


    On December 10, 2020, Apellis and Sweden’s SOBIO Biovitrum AB announced the positive top-line results for the 48th week of the Phase 3 clinical study Pegasus.


    Sanofi: A new drug for Pompe disease (Avalglucosidase Alfa)

    Sanofi's new drug has a biological preparation license application (BLA) target date of May 18 for long-term enzyme replacement therapy for patients with Pompe disease.


    In early February 2021, at the 17th WORLDSymposium conference, Sanofi released data supporting the BLA.


    Bristol-Myers Squibb (BMS): Opdivo adjuvant treatment of esophageal cancer or gastroesophageal junction cancer

    BMS’s target date of action is May 20, and its supplementary BLA is used for Opdivo (nivolumab) to treat neoadjuvant chemoradiotherapy (CRT) after adjuvant treatment of patients with resection of the esophagus or gastroesophageal junction (GEJ) cancer.


    This application is based on the positive results of the Phase 3 clinical trial CheckMate-577.


    ADC Therapeutics: new drug Lonca for diffuse B-cell lymphoma

    The BLA target action date for Lonca (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is May 21.


    The US FDA approved Lonca on April 23, 2021 for patients with r/r large C-cell lymphoma who have received two or more systemic treatments, including DLBCL, non-other specific lymphoma (NOS), and DLBCL caused by low-grade lymphoma, and high-grade B-cell lymphoma.


    Reference source: FDA Action Alert: Heron, Apellis, Sanofi, Merck and ADC

    Reference source: FDA Action Alert: Heron, Apellis, Sanofi, Merck and ADC
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.